Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr
Subgroups of patients with Crohn's disease have different clinical outcomes
β Scribed by Dr. Francesco Perri; Vito Annese; Grazia Napolitano; Nazario Caruso; Rocco Clemente; Maria Rosaria Villani; Angelo Andriulli
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 456 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
β¦ Synopsis
Eighty-three patients with long-standing Crohn's disease (CD) were retrospectively reviewed to determine whether natural history and clinical outcome were different and a patient subgroup classification could be reliably adopted. In all patients, the initial anatomical location, the "behavioral pattern," and the operative history of the disease were evaluated. Two different patterns of disease emerged: the first was characterized by a primarily fistulizing or fibrostenotic "behavior" with severe clinical disease and early requirement for surgery; the second was characterized by a primarily inflammatory "behavior" with a less severe disease and less need for surgery. No correlation of these patterns with gender, age at diagnosis, disease duration, smoking habit, and presence of extraintestinal manifestations could be found. The only other factor significantly related to the clinical course of disease was the anatomical location. The occurrence of two distinct CD patient subgroups with different clinical course and prognosis may have important implications in planning prospective trials and adequate therapeutic strategies.
π SIMILAR VOLUMES
## Background: Patients with Crohn's disease (CD) are prone to osteoporosis. A loss of muscle mass, called sarcopenia, is responsible for an increased risk of disability. Many factors associated with osteopenia also decrease muscle mass. The aim of the present study was to measure the prevalence o
Background: Although a mainstay of treatment of moderate to severe Crohn's disease (CD), corticosteroids use presents significant challenges because of large interindividual variability in response. Corticosteroid-dependence is of particular concern in children, where high rates have been reported.
## Background: Crohn's disease (cd) of the pouch is one of the leading causes of pouch failure in patients with restorative proctocolectomy. risk factors for pouch failure in these patients are yet to be identified. the aim of the study was to assess risk factors associated with pouch failure in pa